 BMO Capital Markets initiated coverage on Graphite Bio Inc NASDAQ: GRPH, with a price target of 12 and an Outperform rating. The analyst notes that Graphites gene editing approach involves a DNA repair mechanism that is known to be less vulnerable to errors. 